CAS: 870087-36-8; 4-(6-(2-(3-Methylbenzylidene)Hydrazinyl)-2-(2-(Pyridin-2-yl)Ethoxy)Pyrimidin-4-yl)Morpholine Dimethanesulfonate

英文名称4-(6-(2-(3-Methylbenzylidene)Hydrazinyl)-2-(2-(Pyridin-2-yl)Ethoxy)Pyrimidin-4-yl)Morpholine Dimethanesulfonate
中文名称阿吡莫德甲磺酸盐
IUPAC名称(E)-4-(6-(2-(3-methylbenzylidene)hydrazineyl)-2-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine dimethanesulfonate
其它别名Apilimod Mesylate; Apilimod Dimesylate; Apilimod Mesylate [usan]; Apilimod (Mesylate); Unii-5G3P5Ok11S; 5G3P5Ok11S; (E)-4-(6-(2-(3-Methylbenzylidene)Hydrazinyl)-2-(2-(Pyridin-2-yl)Ethoxy)Pyrimidin-4-yl)Morpholine
CAS编号870087-36-8
MFCD编号:MFCD28167749
EINECS号:810-042-9
FDA UNII编号:5G3P5OK11S
分子式:C25H34N6O8S2分子量:610.72
产品CID: 1874556
同类组份化合物CAS870087-36-8 (mesylate)541550-19-0 (free base)1383916-59-3 (free base)870087-37-9 (HCl)870151-86-3 (tosylate)870087-41-5 (besylate)
产品分类生物化工 → 生化试剂 → 激动剂抑制剂

相似结构搜索
InChIKey: GAJWNIKZLYZYSY-OKUPSQOASA-N
InChI=1S/C23H26N6O2.2CH4O3S/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20;2*1-5(2,3)4/h2-7,9,15-17H,8,10-14H2,1H3,(H,26
计算化学: 氢键受体数14.0氢键供体数3.0可旋转键数8.0

物理性质

溶解性Soluble In DMSO
外观形态白色至类白色粉末
储存条件储存在 -20°C
产品应用该化合物是细胞内脊髓灰质素-12(IL-12)和内脑脑-23(IIL-23)的有力口服抑制剂,可能对某些自发性免疫和炎症进行治疗;它还充当PIKFYVE的细胞渗透性小分子抑制器.

欧盟法规

C&L通报

合成工艺路线路线简述

海关参考信息

2902300000-甲苯
2909110000-乙醚
2922110001-单乙醇胺
2933310010-吡啶
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-12441733-B2
优先权日:2018-03-26
标题:Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors
发明人：ARISTA LUCA; HEBACH CHRISTINA; HOLLINGWORTH GREGORY JOHN; HOLZER PHILIPP; IMBACH-WEESE PATRICIA; LORBER JULIEN; MACHAUER RAINER; SCHMIEDEBERG NIKO; VULPETTI ANNA; ZOLLER THOMAS
权利人:NOVARTIS AG
摘要:The invention relates to compounds of the formulae (I), (III), (IIIa), (XXIa), (XXIII), and/or (XLVI)or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

1: Cinato M, Guitou L, Saidi A, Timotin A, Sperazza E, Duparc T, Zolov SN, Giridharan SSP, Weisman LS, Martinez LO, Roncalli J, Kunduzova O, Tronchere H, Boal F. Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling. Theranostics. 2021 Apr 19;11(13):6491-6506. doi: 10.7150/thno.55821.
2: Baranov MV, Bianchi F, van den Bogaart G. The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19. Cells. 2020 Dec 27;10(1):30. doi: 10.3390/cells10010030.
3: Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, Burgstaller- Muehlbacher S, De Jesus PD, Teriete P, Hull MV, Chang MW, Chan JF, Cao J, Poon VK, Herbert KM, Cheng K, Nguyen TH, Rubanov A, Pu Y, Nguyen C, Choi A, Rathnasinghe R, Schotsaert M, Miorin L, Dejosez M, Zwaka TP, Sit KY, Martinez- Sobrido L, Liu WC, White KM, Chapman ME, Lendy EK, Glynne RJ, Albrecht R, Ruppin E, Mesecar AD, Johnson JR, Benner C, Sun R, Schultz PG, Su AI, García-Sastre A, Chatterjee AK, Yuen KY, Chanda SK. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020 Oct;586(7827):113-119. doi: 10.1038/s41586-020-2577-1. Epub 2020 Jul 24.